|
|
Type of Company:
Type:
|
Company
|
Ownership: |
Privately Held (Funded) |
Company Size: |
20-49 Employees In BC (50-99 Total)
20-49 In BC (50-99 Total)
|
Year Founded: |
2019 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
Chinook Therapeutics, biotechnology, kidney diseases, therapeutics
|
|
|
|
Chinook Therapeutics is a biotechnology company developing precision medicines for patients with kidney diseases.
We apply our proprietary research platform to discover and develop therapeutics with novel mechanisms of action against key kidney disease pathways. The development focus is on rare, serious disorders with clear unmet medical needs and defined and rapid clinical development opportunities.
Chinook's pipeline currently has several internal programs at the validation and lead optimization stages rapidly progressing for multiple programs to enter clinical trials by 2021. We are also evaluating business development opportunities for early and late-stage clinical assets to enhance the pipeline.
Chinook has raised a $65 million Series A financing from top tier venture capital firms Versant Ventures, Apple Tree Partners, and Samsara BioCapital.
We are a growing team of approximately 25 employees and are based in Vancouver, British Columbia and Seattle, Washington. |
|
|
Date |
Type |
Amount |
Investors |
Aug 21, 2020 |
Private Placement |
$106 Million CAD |
The financing had participation from new investors including EcoR1 Capital, OrbiMed, funds managed by Rock Springs Capital, Avidity Partners, Surveyor Capital (a Citadel company), Ally Bridge Group, Monashee Investment Management LLC, Northleaf Capital Partners, Janus Henderson Investors, Sphera Biotech, and other top-tier healthcare investors.
As part of the financing, Chinook's existing investors, Versant Ventures, Apple Tree Partners and Samsara BioCapital, will purchase $25 million in Chinook common stock on the same terms as the new investors in lieu of their prior commitment to purchase convertible notes. |
Date |
Type |
Amount |
Investors |
Aug 21, 2020 |
Private Placement |
$106M CAD |
The financing had participation from new investors including EcoR1 Capital, OrbiMed, funds managed by Rock Springs Capital, Avidity Partners, Surveyor Capital (a Citadel company), Ally Bridge Group, Monashee Investment Management LLC, Northleaf Capital Partners, Janus Henderson Investors, Sphera Biotech, and other top-tier healthcare investors.
As part of the financing, Chinook's existing investors, Versant Ventures, Apple Tree Partners and Samsara BioCapital, will purchase $25 million in Chinook common stock on the same terms as the new investors in lieu of their prior commitment to purchase convertible notes. |
|
|
|
Want More Chinook Therapeutics, Inc. News? 1
|
Next »
|
|
|
|
Share This Company Profile |
|
|
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
